|

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

RECRUITINGPhase 2Sponsored by Yang Li
Actively Recruiting
PhasePhase 2
SponsorYang Li
Started2023-12-13
Est. completion2031-12-14
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06088030

Summary

This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

1. Pathological diagnosis basis of malignant tumor；
2. Patients not more than 18 years old;
3. Patient has either germline or somatic p53 mutations, which was shown to be partially/completely restored to function by ATO in in vitro experiments (http://www.rescuep53.net);
4. There are measurable lesions;
5. Guardians agreed and signed informed consent.

Exclusion Criteria:

Patients with one or more critical organs failure such as heart, brain, kidney failure.

Conditions4

CancerLi-Fraumeni SyndromePediatric Cancerp53 Mutations

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.